SCHEMBL17384135

SCHEMBL17384135

O=C(OCCO)c1ccc2c(c1)C(=O)N(c1ccc(N3C(=O)c4ccc(C(=O)OCCO)cc4C3=O)cc1)C2=O

nearest known ligand 0.68

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.68
▸ MET P08581 1/20 0.56
▸ CA1 P00915 4/20 0.53
▸ CA9 Q16790 4/20 0.53
▸ CA4 P22748 4/20 0.53
▸ CA2 P00918 3/20 0.53
▸ PTGES O14684 1/20 0.53
▸ LMNA P02545 2/20 0.52
▸ PLA2G1B P04054 1/20 0.51
▸ ATG4B Q9Y4P1 1/20 0.51
▸ MEN1 O00255 2/20 0.50
▸ KMT2A Q03164 2/20 0.50
▸ POLB P06746 1/20 0.49
▸ CA12 O43570 2/20 0.49
▸ MAPT P10636 2/20 0.48
▸ CA7 P43166 1/20 0.48
▸ GFER P55789 1/20 0.48
▸ NPSR1 Q6W5P4 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16644575 0.99 ALDH1A1 (0.67) ALDH1A1METCA1CA9CA4
SCHEMBL17384346 0.94 ALDH1A1 (0.61) ALDH1A1METCA1CA9CA4
SCHEMBL17384242 0.91 ALDH1A1 (0.67) ALDH1A1METCA1CA9CA4
SCHEMBL19004802 0.90 ALDH1A1 (0.61) ALDH1A1METCA1CA9CA4
SCHEMBL18998860 0.90 ALDH1A1 (0.65) ALDH1A1METCA1CA9CA4
SCHEMBL18053289 0.88 ALDH1A1 (0.64) ALDH1A1METCA1CA9CA4
SCHEMBL18998866 0.84 LMNA (0.60) ALDH1A1CA1CA9CA4CA2
SCHEMBL14374920 0.83 LMNA (0.59) ALDH1A1CA1CA9CA4CA2
SCHEMBL18979899 0.83 ALDH1A1 (0.53) ALDH1A1METCA1CA9CA4
SCHEMBL21082656 0.81 PTGES (0.60) ALDH1A1METCA1CA9CA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10450411-B2 Copolyesterimides comprising bis(2-hydroxyalkyl)-2,2′-(1,4-phenylene)bis(1,3-dioxoisoindoline-5-carboxylate) and articles made therefrom DUPONT TEIJIN FILMS U.S. LIMITED PARTNERSHIP (US) 2019-10-22 — — US disclosed
EP-3157977-B1 COPOLYESTERIMIDES COMPRISING BIS(2-HYDROXYALKYL)-2,2'-(1,4-PHENYLENE)BIS(1,3-DIOXOISOINDOLINE-5-CARBOXYLATE) AND ARTICLES MADE THEREFROM DUPONT TEIJIN FILMS US LP (US) 2018-07-18 — — EP disclosed
US-20170174831-A1 COPOLYESTERIMIDES COMPRISING BIS(2-HYDROXYALKYL)-2,2'-(1,4-PHENYLENE)BIS(1,3-DIOXOISOINDOLINE-5-CARBOXYLATE) AND ARTICLES MADE THEREFROM DUPONT TEIJIN FILMS U.S. LIMITED PARTNERSHIP (US) 2017-06-22 — — US disclosed
US-20170174831-A1 COPOLYESTERIMIDES COMPRISING BIS(2-HYDROXYALKYL)-2,2'-(1,4-PHENYLENE)BIS(1,3-DIOXOISOINDOLINE-5-CARBOXYLATE) AND ARTICLES MADE THEREFROM DUPONT TEIJIN FILMS U.S. LIMITED PARTNERSHIP (US) 2017-06-22 — — US disclosed
WO-2015193682-A1 COPOLYESTERIMIDES COMPRISING BIS(2-HYDROXYALKYL)-2,2'-(1,4-PHENYLENE)BIS(1,3-DIOXOISOINDOLINE-5-CARBOXYLATE) AND ARTICLES MADE THEREFROM DUPONT TEIJIN FILMS U.S. LIMITED PARTNERSHIP (US) 2015-12-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10450411-B2 Copolyesterimides comprising bis(2-hydroxyalkyl)-2,2′-(1,4-phenylene)bis(1,3-dioxoisoindoline-5-carboxylate) and articles made therefrom NOTUM, WEE1, WEE2 ALDH1A1 723/4885MET 1425/4885CA1 1876/4885
US-20170174831-A1 COPOLYESTERIMIDES COMPRISING BIS(2-HYDROXYALKYL)-2,2'-(1,4-PHENYLENE)BIS(1,3-DIOXOISOINDOLINE-5-CARBOXYLATE) AND ARTICLES MADE THEREFROM PUF60, PDS5A, DDT ALDH1A1 135/4885MET 1546/4885CA1 1896/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback